KEROS THERAPEUTICS INC KROS

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once ($354.7k this quarter). Holder counts are more reliable. Shares outstanding: 29.6m as of 2023-04-27, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $42.60. Options: 6 managers hold calls ($2.2m notional), 2 hold puts ($4.3k).

Trends to Q1 2023

Options at notional value: the value of the shares the contracts control, as filers report them, not what the options cost. Not included in the holders, shares or buying above.

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

Fell to 5% or below in the last year: VANGUARD GROUP INC (0.0%, 2026-03-27), D. E. SHAW & CO, L.P. (3.9%, 2026-02-17), TANG CAPITAL MANAGEMENT LLC (0.0%, 2026-02-17), ExodusPoint Capital Management, LP (0.0%, 2026-02-17), Madison Avenue Partners, LP (2.7%, 2026-02-17)

Insider purchases and sales in Q1 2023

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

None reported in Q1 2023.

Holders, Q1 2023